4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

OBJECTIVE: To report the efficacy, patient-reported, radiographic and safety outcomes of 4 years’ certolizumab pegol (CZP) treatment in patients with psoriatic arthritis (PsA). METHODS: RAPID-PsA (NCT01087788) was double-blind and placebo-controlled to Week 24, dose-blind to Week 48 and open-label (...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Deodhar, Atul, FitzGerald, Oliver, Fleischmann, Roy, Gladman, Dafna, Gottlieb, Alice B, Hoepken, Bengt, Bauer, Lars, Irvin-Sellers, Oscar, Khraishi, Majed, Peterson, Luke, Turkiewicz, Anthony, Wollenhaupt, Jürgen, Mease, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856919/
https://www.ncbi.nlm.nih.gov/pubmed/29556416
http://dx.doi.org/10.1136/rmdopen-2017-000582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856919/
https://www.ncbi.nlm.nih.gov/pubmed/29556416
http://dx.doi.org/10.1136/rmdopen-2017-000582

Ejemplares similares